Skip to main content

Table 2 CAFS results (mean and standard deviation) at 6 and 12 months in phase I/II clinical trials

From: Efficacy and safety of Lenzumestrocel (Neuronata-R® inj.) in patients with amyotrophic lateral sclerosis (ALSUMMIT study): study protocol for a multicentre, randomized, double-blind, parallel-group, sham procedure-controlled, phase III trial

Point

Group

N

CAFS, mean

CAFS, SD

6 months

Study group

39

40.79

17.52

Control group

27

22.96

16.56

12 months

Study group

39

39.14

18.22

Control group

27

25.35

17.82

Back to article page

Trials

ISSN: 1745-6215